Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.
The company operates in two segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for domestic and international markets.
The product portfolio spans multiple therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Offerings are across dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.
Sai Parenteral's serves a wide customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists in India. The company entered exports in FY 2023 after acquiring two internationally accredited facilities in Hyderabad, Telangana, and now supplies to regulated and semi-regulated markets in Australia, New Zealand, Southeast Asia, the Middle East, and Africa.
The company owns and operates five manufacturing facilities in India. Four are located in Hyderabad, Telangana, comprising a GMP-compliant injectable unit, a WHO-GMP injectable unit, a TGA-Australia and PIC/S accredited solid oral dosage unit, and a WHO-GMP cephalosporin facility. Its wholly owned subsidiary, Revat Laboratories, operates a GMP-certified facility in Ongole, Andhra Pradesh.
As of December 31, 2025, Sai Parenteral Ltd. employed 298 full-time employees.
Competitive Strength:
- Diversified generic formulations player with an established track record.
- Strategically located and accredited Manufacturing Facilities.
- Strong focus on CDMO business.
- Well-established distribution network in India and overseas.
- Track record of value-accretive acquisitions.
- Experienced Promoters and Senior Management with extensive domain knowledge.
| Purpose | Amount (₹ Cr) |
|---|---|
| Capacity expansion and upgradation of manufacturing facilities | ₹110.80 |
| Establishment of a new R&D Centre; | ₹18.02 |
| Repayment / prepayment of certain outstanding borrowings | ₹14.30 |
| Repayment / prepayment of certain outstanding borrowings | ₹33.00 |
| Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and | ₹35.64 |
| General corporate purposes | — |
| Metric | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Total Assets | 376.24 | 272.39 | 268.10 |
| Revenue | 89.43 | 163.74 | 155.18 |
| PAT | 7.76 | 14.43 | 8.42 |
| EBITDA | 16.24 | 39.44 | 31.70 |
| Net Worth | 209.37 | 95.78 | 76.40 |
| Reserves | 188.84 | 80.36 | 61.30 |
| Total Borrowing | 76.07 | 93.95 | 118.79 |
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 52,14,144 (50.00%) | — | ₹204.39 Cr |
| NII / HNI | — | 15,64,243 (15.00%) | — | ₹61.32 Cr |
| Retail (RII) | — | 36,49,901 (35.00%) | — | ₹143.08 Cr |
| Total | — | 1,04,28,288 (100.00%) | — | ₹408.79 Cr |
* Amount calculated at upper price band (₹392) · ** Total includes all investor categories
- 1 Initiation of Refund 01 Apr 2026
- 2 Credit of Shares to Demat 01 Apr 2026
- 3 Lock-in Period (30%) Wed, Apr 29, 2026
- 4 Lock-in Period (50%) Sun, Jun 28, 2026
- Retail allocation is good at 35.0% of the total offering.
- HNI/NII demand is good at 15.0%.
- Institutional (QIB) interest is strong at 50.0%.
- The IPO P/E of 72.19x reflects a weak valuation relative to typical market ranges.
- Pre-issue EPS of ₹5.43.
This IPO shows moderate investor interest. Review financial details and compare valuation with industry peers before investing.
The information on mainboardgmp.com is provided for educational and informational purposes only.
We are not a Securities and Exchange Board of India (SEBI)-registered investment advisor, analyst, broker, or financial planner. The content, data, and insights on this website, including Grey Market Premium (GMP), subscription data, IPO dates, and market information, are not intended as financial advice or recommendations to buy, sell, or hold securities.
GMP and related IPO data are collected from unofficial market sources and may not reflect actual IPO listing performance or future price movements. You should not rely solely on the information provided here to make financial or investment decisions.
Investing in IPOs and securities involves risk. Always conduct your own research and consult a qualified SEBI-registered financial advisor before making investment decisions. mainboardgmp.com and its owners shall not be liable for any financial losses, trading losses, or damages arising from use of this website.
By accessing and using mainboardgmp.com, you agree to be bound by these Terms & Conditions. If you do not agree with any part of these terms, you should not use this website.
mainboardgmp.com provides information related to IPOs, including Grey Market Premium (GMP), subscription status, IPO dates, company details, and market trends. All content is for informational purposes only.
Nothing on this website constitutes financial, investment, tax, or legal advice. The content does not constitute a recommendation to invest in any securities, and no assurance is made regarding the accuracy, completeness, or reliability of any information. You should independently verify all information and consult qualified professionals before making investment decisions.
We strive to provide accurate and up-to-date information, but we do not guarantee that all content is correct, complete, or current at all times. IPO details and GMP data are subject to change without notice.
All content, design, graphics, and data on this website belong to mainboardgmp.com and may not be copied, reproduced, or redistributed without express written permission.
You agree not to use the website for unlawful purposes or in a way that may harm, disable, or impair the site's operation.
To the maximum extent permitted by law, mainboardgmp.com and its affiliates shall not be liable for any losses, damages, costs, or expenses arising out of your use of this website.
These Terms shall be governed by the laws of India. Any disputes will be subject to the exclusive jurisdiction of courts located in Kolkata, West Bengal.
We reserve the right to modify these Terms at any time. Continued use of the site constitutes acceptance of the updated Terms.
We may collect: email address (if submitted voluntarily), IP address, browser and device information, cookies and usage data. We do not collect sensitive personal information unless voluntarily provided.
Collected data may be used to improve website performance, respond to inquiries, send newsletters or updates (if you subscribe), and analyze traffic through analytics tools.
We use cookies and similar technologies to enhance user experience and track website usage. Users can disable cookies through browser settings.
We may use third-party services (e.g., Google Analytics) that collect demographic and usage data to help us understand traffic and improve services.
We do not sell personal information. We may share data with service providers (e.g., analytics providers) who assist with website operations.
Reasonable measures are taken to protect user data, but no online transmission can be guaranteed 100% secure.
This website is not directed at children under the age of 18.
We may update this Privacy Policy at any time. Continued use of the website constitutes acceptance of changes.
For privacy concerns, please contact us via the Support page.